Market Cap 162.56M
Revenue (ttm) 0.00
Net Income (ttm) -19.00M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 152,600
Avg Vol 173,030
Day's Range N/A - N/A
Shares Out 20.89M
Stochastic %K 29%
Beta -0.25
Analysts Strong Sell
Price Target $19.25

Company Profile

Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. Its lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trial for the treatment of patients with platinum-resistant ARID1a-mutated ovarian carcinoma. The company is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trial that inhibits th...

Industry: Biotechnology
Sector: Healthcare
Phone: 201 614 3150
Address:
1 Bridge Plaza, Suite 275, Fort Lee, United States
BioTrade2
BioTrade2 Jul. 28 at 5:46 PM
$NVCT “No one sits on good data”
1 · Reply
WallStWireAds
WallStWireAds Jul. 27 at 8:41 PM
$NVCT NXP900: The Breakthrough Drug That Could Transform Nuvectis Pharma Into a Multi-Billion Dollar Biotech Giant https://venture-block.com/nxp900-the-breakthrough-drug-that-could-transform-nuvectis-pharma-into-a-multi-billion-dollar-biotech-giant/
0 · Reply
buyandsold
buyandsold Jul. 26 at 11:16 PM
$NVCT what does it pop to on NXP800?
1 · Reply
BioSensai
BioSensai Jul. 24 at 7:03 PM
$NVCT yesterday 1.5mm shares were traded as single block. Who was the buyer?
1 · Reply
ZR92x
ZR92x Jul. 24 at 6:55 PM
$NVCT Final comments - NXP800 sentiment is low, but if it surprises to the upside, I think it could lead to a dramatic change in the sentiment for this entire company even with NXP800 having a much lower TAM than NXP900. NXP900 is the main prize, but I am hopeful for good NXP800 data in the next few weeks. GLTA
1 · Reply
BioSensai
BioSensai Jul. 24 at 6:40 PM
$NVCT @cupcakes4jesus is fairly certain this big volume is from ATM usage. My understanding is with issuing shares ATM it takes buyers to do that otherwise price drops as it is dilution with no buying. Seems 1.5mm shares is A LOT and too much at once for a small daily volume of less than 100k shares.. A direct offering to a buyer makes more sense. thoughts?
2 · Reply
ZR92x
ZR92x Jul. 24 at 6:17 PM
$NVCT continuing from my comments below - I have been primarily in this for NXP900 data but dont sleep on NXP800 at all just because they didn’t talk about it much at the HCW conference
0 · Reply
ZR92x
ZR92x Jul. 24 at 6:09 PM
$NVCT i think Charles or someone keeps buying more - another big batch of $12 million or so yesterday. Are they buying for NXP800 or NXP900 or both? I am hoping for a nice surprise on NXP800 soon. If it’s good, I hope that Wall Street values it beyond just the ARID1a ovarian indication and into endometrial and possibly others with the ARID1a mutation. could be a few billion+ in TAM with read-through into these other indications. combined with NXP900 this could be a monster… I am willing to keep waiting. long time holder and lurker here
0 · Reply
cupcakes4jesus
cupcakes4jesus Jul. 23 at 8:13 PM
$NVCT more like tapping the ATM for 1.5m shares. Not a good sign given its open label data and they can see the data. Very odd they would tap the ATM so aggressively days before a crucial readout. Very sus to say the least.
0 · Reply
BioSensai
BioSensai Jul. 23 at 7:30 PM
$NVCT big things imminent!
1 · Reply
Latest News on NVCT
Nuvectis Pharma to Present at the 36th Annual Roth Conference

Mar 15, 2024, 8:00 AM EDT - 1 year ago

Nuvectis Pharma to Present at the 36th Annual Roth Conference


Nuvectis: Early Stage Company That's Low On Cash

Sep 6, 2023, 8:03 AM EDT - 2 years ago

Nuvectis: Early Stage Company That's Low On Cash


Nuvectis Pharma Announces FDA Clearance of NXP900 IND

May 15, 2023, 8:00 AM EDT - 2 years ago

Nuvectis Pharma Announces FDA Clearance of NXP900 IND


Nuvectis Pharma Announces FDA Clearance of IND for NXP800

Jun 21, 2022, 8:15 AM EDT - 3 years ago

Nuvectis Pharma Announces FDA Clearance of IND for NXP800


BioTrade2
BioTrade2 Jul. 28 at 5:46 PM
$NVCT “No one sits on good data”
1 · Reply
WallStWireAds
WallStWireAds Jul. 27 at 8:41 PM
$NVCT NXP900: The Breakthrough Drug That Could Transform Nuvectis Pharma Into a Multi-Billion Dollar Biotech Giant https://venture-block.com/nxp900-the-breakthrough-drug-that-could-transform-nuvectis-pharma-into-a-multi-billion-dollar-biotech-giant/
0 · Reply
buyandsold
buyandsold Jul. 26 at 11:16 PM
$NVCT what does it pop to on NXP800?
1 · Reply
BioSensai
BioSensai Jul. 24 at 7:03 PM
$NVCT yesterday 1.5mm shares were traded as single block. Who was the buyer?
1 · Reply
ZR92x
ZR92x Jul. 24 at 6:55 PM
$NVCT Final comments - NXP800 sentiment is low, but if it surprises to the upside, I think it could lead to a dramatic change in the sentiment for this entire company even with NXP800 having a much lower TAM than NXP900. NXP900 is the main prize, but I am hopeful for good NXP800 data in the next few weeks. GLTA
1 · Reply
BioSensai
BioSensai Jul. 24 at 6:40 PM
$NVCT @cupcakes4jesus is fairly certain this big volume is from ATM usage. My understanding is with issuing shares ATM it takes buyers to do that otherwise price drops as it is dilution with no buying. Seems 1.5mm shares is A LOT and too much at once for a small daily volume of less than 100k shares.. A direct offering to a buyer makes more sense. thoughts?
2 · Reply
ZR92x
ZR92x Jul. 24 at 6:17 PM
$NVCT continuing from my comments below - I have been primarily in this for NXP900 data but dont sleep on NXP800 at all just because they didn’t talk about it much at the HCW conference
0 · Reply
ZR92x
ZR92x Jul. 24 at 6:09 PM
$NVCT i think Charles or someone keeps buying more - another big batch of $12 million or so yesterday. Are they buying for NXP800 or NXP900 or both? I am hoping for a nice surprise on NXP800 soon. If it’s good, I hope that Wall Street values it beyond just the ARID1a ovarian indication and into endometrial and possibly others with the ARID1a mutation. could be a few billion+ in TAM with read-through into these other indications. combined with NXP900 this could be a monster… I am willing to keep waiting. long time holder and lurker here
0 · Reply
cupcakes4jesus
cupcakes4jesus Jul. 23 at 8:13 PM
$NVCT more like tapping the ATM for 1.5m shares. Not a good sign given its open label data and they can see the data. Very odd they would tap the ATM so aggressively days before a crucial readout. Very sus to say the least.
0 · Reply
BioSensai
BioSensai Jul. 23 at 7:30 PM
$NVCT big things imminent!
1 · Reply
BioSensai
BioSensai Jul. 23 at 7:07 PM
$NVCT I smell a direct offering of 1.5mm share pr soon. It seems the only way big money is able to load up
0 · Reply
F4651110
F4651110 Jul. 23 at 6:55 PM
$NVCT signs could possibly indicate news tomorrow. Company usually announce news on Thursdays pre-market
0 · Reply
BioSensai
BioSensai Jul. 23 at 6:49 PM
$NVCT Something big happened today with a 1.5mm share buy a bit over $8. We will hear something within the next 24 hours
2 · Reply
essiepaul
essiepaul Jul. 23 at 5:13 PM
$NVCT more games by short sellers? The bs never ends in the den of thieves
1 · Reply
BioTrade2
BioTrade2 Jul. 23 at 2:07 PM
$NVCT sitting and looking at ABVX
1 · Reply
BioSensai
BioSensai Jul. 22 at 4:03 PM
$NVCT Data imminent. AH today to Thursday
0 · Reply
BioSensai
BioSensai Jul. 21 at 4:24 PM
$NVCT data this week friends
1 · Reply
UNLV
UNLV Jul. 21 at 3:15 PM
$NVCT FDA fast track process NXP800 comes with lower bar for approval. Trial needs stable disease or partial response/tumor shrinkage with limited toxicity. CEO referenced stable disease and tumor shrinkage around 50mg intermittent dosing. Seems 75mg intermittent will meet efficacy standards, side effects a ? answered by recent insider buys imo
0 · Reply
cupcakes4jesus
cupcakes4jesus Jul. 20 at 3:09 AM
$NVCT I take all of what I said back about @BioSensai … we’re back to being good pals
0 · Reply
cupcakes4jesus
cupcakes4jesus Jul. 20 at 1:09 AM
$NVCT live picture of @BioSensai
0 · Reply
cupcakes4jesus
cupcakes4jesus Jul. 20 at 1:02 AM
$NVCT @BioSensai aka Nicholas Meyer is probably the biggest idiot I have ever come across on any platform I’ve ever been on. He belongs on TikTok twerking and showing off his body. Not on X or StockTwits. The guy changes from bear to bull to bear back to bull over night, and is a literal reet. He repeats the same 3 sentences 50+ times per day on this name. What a loser. Blocked!
0 · Reply
essiepaul
essiepaul Jul. 19 at 9:38 AM
$NVCT dam stock has missed entire bull move in market over the last 3 years. Except for a couple of trade-able moves you would have been much better off in a CD or an S&P 500 index fund
2 · Reply